COMPLETED

Quantitation of Glymphatic Functioning in Sleep and Meditative States

Conditions

Parkinson Disease Sleep glymphatic system meditation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This involves development and application of magnetic resonance imaging (MRI) methods for visualizing hemodynamic and metabolic relationships in healthy volunteers with advanced meditation experience.

Official Title

Quantitation of Glymphatic Functioning in Sleep and Meditative States

Quick Facts

Study Start:2021-02-01

Study Completion:2024-12-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT04506892

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Ages 14-45 * "Adept meditator status"	* Any non-MR compatible material implant, or contraindication to MR scanning * Claustrophobia or inability to lie still for prolonged periods of time * Participants with a recent (less than 2 months) infection, tattoo, or wound * No consumption of stimulants or alcohol within 12 hours of the study visit * clinical diagnosis of any major neurological or psychological condition * Taking benzodiazepines, cholinestorase inhibitors, anti-psychotics, opioids, MAO inhibitors

Inclusion Criteria

Exclusion Criteria

* Ages 14-45
* "Adept meditator status"

* Any non-MR compatible material implant, or contraindication to MR scanning
* Claustrophobia or inability to lie still for prolonged periods of time
* Participants with a recent (less than 2 months) infection, tattoo, or wound
* No consumption of stimulants or alcohol within 12 hours of the study visit
* clinical diagnosis of any major neurological or psychological condition
* Taking benzodiazepines, cholinestorase inhibitors, anti-psychotics, opioids, MAO inhibitors

Contacts and Locations

Principal Investigator

Daniel Claassen, MD

PRINCIPAL_INVESTIGATOR

Vanderbilt University Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center

Nashville, Tennessee, 37212-3160

United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

Daniel Claassen, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-02-01

Study Completion Date2024-12-01

Study Record Updates

Study Start Date2021-02-01

Study Completion Date2024-12-01

Terms related to this study

Keywords Provided by Researchers

glymphatic system
meditation

Additional Relevant MeSH Terms

Parkinson Disease
Sleep